The biopharmaceutical company Shire Announces Launch of Equasym (methylphenidate hydrochloride, modified-release hard capsules), after approval by the Spanish Agency for Medicines and Health Products (AEMP) for the treatment of ADHD.
Sustained release preparations have similar therapeutic effects to immediate release, and they differ from each other by the plasma concentration time profiles during the day, que se reflejan en los efectos farmacodinámicos. Equasym efficiency is higher in the morning, mientras que otras formulaciones como Concerta, allow better control of symptoms in the evening. Estas diferencias son importantes a la hora de prescribir el tratamiento.
analysis Equasym (Comparison with: Concerta, Medikinet, Strattera y Rubifen)